Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 839-734-9 | CAS number: 2290526-77-9
Endpoint summary
Administrative data
Description of key information
OECD 442C: non-sensitizer
OECD 442D: non-sensitizer
OECD 442E: non-sensitizer
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2019-06-25 to 2019-07-04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Qualifier:
- according to guideline
- Guideline:
- other: Direct Peptide Reactivity Assay (DPRA) for Skin Sensitization Testing, DB-ALM Protocol n°154, January 12, 2013
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- other: (in chemico) reactivity against synthetic peptides with a thiol or amino group
- Specific details on test material used for the study:
- Name: Cyclic Glucamide C8-C10
Chemical Name: Amides, C8-C10, N-(1-deoxy-D-glucitol-1-yl)-N-methyl, dehydrated (CAS name)
Batch No.: BP 1c (reactor mix)
CAS No.: 2290526-77-9
Compounds: Cyclic N-octanoyl-N-methylglucamine 49.9%
Cyclic N-decanoyl-N-methylglucamine 33.2%
N-octanoyl-N-methylglucamine 3.7%
N-decanoyl-N-methylglucamine 2.4%
N-methylglucamine 0.6%
Sorbitol 1.1%
Octanoic acid 0.1%
Decanoic acid 0.2%
Unidentified components 8.5%
Water 0.3%
Physical State: Highly viscous mass (at 20 °C)
Colour: Brown
Stability: Stable
Storage Conditions: At room temperature
Expiry Date: 28 March 2021
Safety Precautions: The routine hygienic procedures were sufficient to assure personnel health and safety. - Details on the study design:
- The in chemico direct peptide reactivity assay (DPRA) enables detection of the sensitising potential of a test item by quantifying the reactivity of test chemicals towards synthetic peptides containing either lysine or cysteine.
- Positive control results:
- The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 64.74%.
- Key result
- Run / experiment:
- other: cysteine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 0
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: lysine run
- Parameter:
- other: mean peptide depletion [%]
- Value:
- 0.2
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Other effects / acceptance of results:
- Acceptance Criteria
The run meets the acceptance criteria if:
- the standard calibration curve has a r² > 0.99,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is
between 60.8% and 100% for the cysteine peptide and the maximum standard deviation (SD) for the
positive control replicates is < 14.9%,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is
between 40.2% and 69.0% for the lysine peptide and the maximum SD for the positive control
replicates is < 11.6%,
- the mean peptide concentration of the three reference controls A replicates is 0.50 ± 0.05 mM,
- the coefficient of variation (CV) of peptide peak areas for the six reference control B replicates and three reference control C replicates in acetonitrile is < 15.0%.
The results of the test item meet the acceptance criteria if:
- the maximum standard deviation (SD) for the test chemical replicates is < 14.9% for the cysteine
percent depletion (PPD),
- the maximum standard deviation (SD) for the test chemical replicates is < 11.6% for the lysine
percent depletion (PPD),
- the mean peptide concentration of the three reference controls C replicates in the appropriate solvent is 0.50 ± 0.05 mM.
Both peptide runs and the test item results met the acceptance criteria of the test. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this study under the given conditions the test item showed minimal reactivity towards both peptides. The test item is considered as “non-sensitiser”.
The data generated with this method may be not sufficient to conclude on the absence of skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. - Executive summary:
In the present study Cyclic Glucamide C8-C10 was dissolved in dist. water : acetonitrile 1:1 (v/v), based on the results of the pre-experiments.
The molecular weight and purity of the mixture was derived from all components (excluding water and unidentified components). Based on the derived molecular weight of 313 g/mol a 100 mM stock solution was prepared. For the water and the unknown components the test item was corrected with a factor of 1.1. All test item preparations were tested in parallel by incubating the samples with the peptides containing either cysteine or lysine for 24 ± 2 h at 25 ± 2.5 °C. Subsequently, samples were analysed by HPLC analysis.
All test item solutions were freshly prepared immediately prior to use.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for any of the samples.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the lysine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for the samples of the test item. Phase separation was observed for the samples of the positive control (including the co-elution control). Samples were not centrifuged prior to the HPLC analysis.
Since the acceptance criteria for the depletion range of the positive control were fulfilled, the observed phase separation was regarded as not relevant.
No co-elution of test item with the peptide peaks was observed. Sensitising potential of the test item was predicted from the mean peptide depletion of both analysed peptides (cysteine and lysine) by comparing the peptide concentration of the test item treated samples to the corresponding reference control C (RC Cdist. water : acetonitrile 1:1 (v/v)).
The 100 mM stock solution of the test item showed minimal reactivity towards the synthetic peptides. The mean depletion of both peptides was ≤6.38% (0.10%). The unidentified components seemed not have influenced the test item, therefore, based on the prediction model 1 the test item can be considered as non-sensitiser.
The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 64.74%.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2019-06-25 to 2019-07-16
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guidelines for Testing of Chemicals, No. 442E: In Vitro Skin Sensitisation assays addressing the Key Event on activation of dendritic cells on the Adverse Outcome Pathway for Skin Sensitisation”, adopted 25 June 2018
- Qualifier:
- according to guideline
- Guideline:
- other: Human Cell Line Activation Test (h-CLAT) for Skin Sensitisation, DB-ALM Protocol n°158, July 1st, 2015
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- activation of dendritic cells
- Specific details on test material used for the study:
- Name: Cyclic Glucamide C8-C10
Chemical Name: Amides, C8-C10, N-(1-deoxy-D-glucitol-1-yl)-N-methyl, dehydrated (CAS name)
Batch No.: BP 1c (reactor mix)
CAS No.: 2290526-77-9
Compounds: Cyclic N-octanoyl-N-methylglucamine 49.9%
Cyclic N-decanoyl-N-methylglucamine 33.2%
N-octanoyl-N-methylglucamine 3.7%
N-decanoyl-N-methylglucamine 2.4%
N-methylglucamine 0.6%
Sorbitol 1.1%
Octanoic acid 0.1%
Decanoic acid 0.2%
Unidentified components 8.5%
Water 0.3%
Physical State: Highly viscous mass (at 20 °C)
Colour: Brown
Log KOW: Not applicable
Stability: Stable
Storage Conditions: At room temperature
Expiry Date: 28 March 2021
Safety Precautions: The routine hygienic procedures were sufficient to assure personnel health and safety. - Details on the study design:
- The in vitro human cell line activation test (h-CLAT) enables detection of the sensitising potential of a test
item by addressing the third molecular key event of the adverse outcome pathway (AOP), namely
dendritic cell activation, by quantifying the expression of the cell surface markers CD54 and CD86 in
the human monocytic cell line THP-1. The expression of the cell surface markers compared to the
respective solvent controls is used to support discrimination between skin sensitisers and
non-sensitisers. - Positive control results:
- The positive control (DNCB) led to an upregulation of the expression of CD54 and CD86 in both
experiments. The threshold of 150% for CD86 (347% experiment 1; 306% experiment 2) and
200% for CD54 (338% experiment 1; 477% experiment 2) were clearly exceeded. - Key result
- Run / experiment:
- other: 1
- Parameter:
- other: relative fluorescence intensity CD86 [%]
- Value:
- 108
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 410.23 µg/mL
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: relative fluorescence intensity CD54 [%]
- Value:
- 113
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 237.40 µg/mL
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: relative fluorescence intensity CD86 [%]
- Value:
- 108
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 197.84 µg/mL
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: relative fluorescence intensity CD54 [%]
- Value:
- 141
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 284.88 µg/mL
- Other effects / acceptance of results:
- Acceptance criteria:
The test meets acceptance criteria if:
• the cell viability of the solvent controls is >90%,
• the cell viability of at least four tested doses of the test item in each run is >50%,
• the RFI values of the positive control (DNCB) is ≥150% for CD86 and ≥200% for CD54 at a cell viability of >50%,
• the RFI values of the solvent control is not ≥150% for CD86 and not ≥200% for CD54,
• the MFI ratio of CD86 and CD54 to isotype IgG1 control for the medium and DMSO control, is >105%.
The test mets the acceptance criteria. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this study under the given conditions the test item did not upregulate the expression of the cell surface markers in at least two independent experiment runs. Therefore, the test item might be considered as non-sensitiser.
The data generated with this method may be not sufficient to conclude on the absence of skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. - Executive summary:
In the present study Cyclic Glucamide C8-C10 was dissolved in DMSO. For the dose finding assay stock solutions with concentrations ranging from 500 mg/mL to 3.91 mg/mL were prepared by a serial dilution of 1:2. Cells were incubated with the test item for 24 h at 37°C. After exposure cells were stained with propidium iodide and cell viability was measured by FACS analysis.
A CV75 of 410.23 ± 140.29 µg/mL was derived in the dose finding assay. Based on the CV75, the main experiment was performed covering the following concentration steps:
492.28, 410.23, 341.86, 284.88, 237.40, 197.84, 164.86, 137.39 µg/mL
In all experiments no precipitation or turbidity of the test item was observed for all concentration steps when mixing the test item stock solutions with cell culture medium.
Cells were incubated with the test item for 24 h at 37°C. After exposure cells were stained and cell surface markers CD54 and CD86 were measured by FACS analysis. Cell viability was assessed in parallel using propidium iodide staining.
Cytotoxic effects were observed for the cells treated with the test item. Relative cell viability at the highest test item concentration was reduced to 19.1% (CD86), 21.4% (CD54) and 20.0% (isotype IgG1 control) in the first experiment and to 27.7% (CD86), 26.1% (CD54) and 25.9% (isotype IgG1 control) in the second experiment.
The expression of the cell surface marker CD86 was not upregulated above the threshold of 150% in any of the experiments. The expression of the cell surface marker CD54 was not upregulated above the threshold of 200% in any of the experiments. Therefore, the test item can be considered as non-sensitiser.
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2019-06-18 to 2019-08-23
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
- Qualifier:
- according to guideline
- Guideline:
- other: KeratinoSens™, EURL ECVAM DB-ALM Protocol No. 155, July 1st, 2015
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- activation of keratinocytes
- Specific details on test material used for the study:
- Name: Cyclic Glucamide C8-C10
Chemical Name: Amides, C8-C10, N-(1-deoxy-D-glucitol-1-yl)-N-methyl, dehydrated (CAS name)
Batch No.: BP 1c (reactor mix)
CAS No 2290526-77-9
Compounds: Cyclic N-octanoyl-N-methylglucamine 49.9%
Cyclic N-decanoyl-N-methylglucamine 33.2%
N-octanoyl-N-methylglucamine 3.7%
N-decanoyl-N-methylglucamine 2.4%
N-methylglucamine 0.6%
Sorbitol 1.1%
Octanoic acid 0.1%
Decanoic acid 0.2%
Unidentified components 8.5%
Water 0.3%
Physical State: highly viscous mass (at 20 °C)
Colour: brown
Log KOW not specified by the Sponsor
Stability: stable
Storage Conditions: at room temperature
Expiry Date: 28 March 2021
Safety Precautions: The routine hygienic procedures were sufficient to assure personnel health and safety. - Details on the study design:
- The in vitro KeratinoSens™ assay enables detection of the sensitising potential of a test item by
addressing the second molecular key event of the adverse outcome pathway (AOP), namely
activation of keratinocytes, by quantifying the luciferase activity in the transgenic cell line
KeratinoSens™. The luciferase activity, assessed by luminescence measurement, compared
to the respective solvent controls is used to support discrimination between skin sensitisers
and non-sensitisers. - Positive control results:
- The luciferase activity induced by the positive control at a concentration of 64 µM was between 2 and 8 (3.38 (experiment 1); 2.50 (experiment 2) and 3.32 (experiment 3)).
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: luciferase activity
- Value:
- 1.75
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 500 µM
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: cell viability [%]
- Value:
- 70.7
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: 1
- Parameter:
- other: EC1.5 [µM]
- Value:
- 337.79
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other:
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: luciferase activity
- Value:
- 1.43
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration: 500 µM
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: cell viability [%]
- Value:
- 74.5
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Run / experiment:
- other: 2
- Parameter:
- other: EC1.5 [µM]
- Value:
- 921.83
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other:
- Run / experiment:
- other: 3
- Parameter:
- other: luciferase activity
- Value:
- 1.26
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Concentration 0.98 µM
- Run / experiment:
- other: 3
- Parameter:
- other: cell viability [%]
- Value:
- 82
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Run / experiment:
- other: 3
- Parameter:
- other: EC1.5 [µM]
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- not determinable
- Other effects / acceptance of results:
- Acceptance Criteria
The test meets acceptance criteria if:
- the luciferase activity induction of the positive control is statistically significant above the threshold of 1.5 (using a t-test) in at least one of the tested concentrations
- the average induction in the three technical replicates for the positive control at a concentration of
64 µM is between 2 and 8
- the EC1.5 value of the positive control is within two standard deviations of the historical mean
- the average coefficient of variation (CV; consisting of 6 wells) of the luminescence reading for the
negative (solvent) control DMSO is <20% in each repetition.
The controls fullfilled the validity criteria of the test. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this study under the given conditions the test item did not induce the luciferase activity in the transgenic KeratinoSens™ cell line in at least two independent experiment runs. Therefore, the test item can be considered as non-sensitiser.
The data generated with this method may be not sufficient to conclude on the absence of skin sensitisation potential of chemicals and should be considered in the context of integrated approach such as IATA. - Executive summary:
In the present study Cyclic Glucamide C8-C10 was dissolved in DMSO. Based on a calculated molecular weight of 312.89 g/mol a stock solution of 200 mM was prepared. The test item contained 8.5% unidentified components, therefore, it was corrected with a correction factor of 1.1.
Based on the stock solution a set of twelve master solutions in 100% solvent was prepared by serial dilution using a constant dilution factor of 1:2. These master solutions were diluted 1:100 in cell culture medium. The following concentration range was tested in the assay:
2000, 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98 µM
Cells were incubated with the test item for 48 h at 37°C. After exposure cells were lysed and luciferase activity was assessed by luminescence measurement.
In the first experiment, a max luciferase activity (Imax) induction of 2.24 was determined at a test item concentration of 1000 µM. The corresponding cell viability was 16.9%. The lowest tested concentration with a significant luciferase induction >1.5 (1.75) was found to be 500 µM. The corresponding cell viability was >70% (70.7%).The calculated EC1.5 was <1000 µM (337.79 µM).
In the second experiment, a max luciferase activity (Imax) induction of 1.51 was determined at a test item concentration of 1000 µM. The corresponding cell viability was 15.0%. This was the only concentration with a significant luciferase induction >1.5. The calculated EC1.5 was <1000 µM (921.81 µM).
In the third experiment, no significant luciferase induction > 1.5 was found in the tested concentration range. Therefore, no EC1.5 value could be calculated.
A dose-response for luciferase activity induction could be observed for the first run but not for the third run. Therefore, under the condition of this study, the test item is considered as non-sensitiser.
Referenceopen allclose all
Cysteine and Lysine Values of the Calibration Curve
Sample |
Cysteine Peptide |
Lysine Peptide |
||
Peak Area at 220 nm |
Peptide Concentration [mM] |
Peak Area at 220 nm |
Peptide Concentration [mM] |
|
STD1 |
17.9760 |
0.5340 |
16.3790 |
0.5340 |
STD2 |
9.1180 |
0.2670 |
8.1840 |
0.2670 |
STD3 |
4.4450 |
0.1335 |
4.0750 |
0.1335 |
STD4 |
2.2080 |
0.0667 |
2.0370 |
0.0667 |
STD5 |
1.0650 |
0.0334 |
1.0270 |
0.0334 |
STD6 |
0.4970 |
0.0167 |
0.5160 |
0.0167 |
STD7 |
0.0000 |
0.0000 |
0.0000 |
0.0000 |
Depletion of the Cysteine Peptide
Cysteine Peptide |
||||||
Sample |
Peak Area at 220 nm |
Peptide Concentration [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
5.3190 |
0.1583 |
69.09 |
69.28 |
0.17 |
0.25 |
5.2800 |
0.1572 |
69.32 |
||||
5.2600 |
0.1566 |
69.44 |
||||
Test Item |
17.1670 |
0.5086 |
0.00 |
0.00 |
0.00 |
n/a |
17.2070 |
0.5098 |
0.00 |
||||
17.2300 |
0.5105 |
0.00 |
||||
Depletion of the Lysine Peptide
Lysine Peptide |
||||||
Sample |
Peak Area at 220 nm |
Peptide Concentration [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
6.2210 |
0.2030 |
59.84 |
60.19 |
0.32 |
0.53 |
6.1260 |
0.1999 |
60.45 |
||||
6.1510 |
0.2007 |
60.29 |
||||
Test Item |
15.2630 |
0.4978 |
0.00 |
0.20 |
0.35 |
173.21 |
15.2560 |
0.4975 |
0.00 |
||||
15.1470 |
0.4940 |
0.61 |
||||
Prediction Model 1
Cysteine 1:10/ Lysine 1:50 Prediction Model 1
Mean Cysteine andLysine PPD |
Reactivity Class |
DPRA Prediction² |
0.00% ≤ PPD ≤ 6.38% |
No or Minimal Reactivity |
Negative |
6.38% < PPD ≤ 22.62% |
Low Reactivity |
Positive |
22.62% < PPD ≤ 42.47% |
Moderate Reactivity |
|
42.47% < PPD ≤ 100% |
High Reactivity |
1 The numbers refer to statistically generated threshold values and are not related to the precision of the measurement.
2 DPRA predictions should be considered in the framework of an IATA.
Prediction Model 2
Cysteine 1:10 Prediction Model
Cysteine PPD |
ReactivityClass |
DPRA Prediction² |
0.00% ≤ PPD ≤ 13.89% |
No or Minimal Reactivity |
Negative |
13.89% < PPD ≤ 23.09% |
Low Reactivity |
Positive |
23.09% < PPD ≤ 98.24% |
Moderate Reactivity |
|
98.24% < PPD ≤ 100% |
High Reactivity |
Categorization of the Test Item
Prediction Model |
Prediction Model 1 (Cysteine Peptide and Lysine Peptide / Item Ratio: 1:10 and 1:50) |
Prediction Model 2 (Cysteine Peptide / Test Item Ratio: 1:10) |
||||
Test Substance |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Test Item |
0.10 |
Minimal Reactivity |
negative |
0.00 |
Minimal Reactivity |
negative |
Positive Control |
64.74 |
High Reactivity |
positive |
69.28 |
Moderate Reactivity |
positive |
Results of the Cell Batch Activation Test (Batch 6)
Sample |
Concentration |
CD86 |
CD54 |
Activated |
Pass /Fail |
||||
Cell Viability [%] |
RFI |
Threshold OECD TG 442E |
Cell Viability [%] |
RFI |
Threshold OECD TG 442E |
yes/no |
|||
DNCB |
4 µg/mL |
85.4 |
327 |
>150 |
85.6 |
287 |
>200 |
yes |
pass |
NiSO4 |
100 µg/mL |
86.7 |
251 |
>150 |
86.5 |
269 |
>200 |
yes |
pass |
LA |
1000 µg/mL |
96.5 |
76 |
≤150 |
96.6 |
77 |
≤200 |
no |
pass |
Results of the Cell Batch Activation Test (Batch 7)
Sample |
Concentration |
CD86 |
CD54 |
Activated |
Pass /Fail |
||||
Cell Viability [%] |
RFI |
Threshold OECD TG 442E |
Cell Viability [%] |
RFI |
Threshold OECD TG 442E |
yes/no |
|||
DNCB |
4 µg/mL |
86.9 |
422 |
>150 |
85.4 |
647 |
>200 |
yes |
pass |
NiSO4 |
100 µg/mL |
89.1 |
254 |
>150 |
90.0 |
454 |
>200 |
yes |
pass |
LA |
1000 µg/mL |
97.9 |
53 |
≤150 |
98.0 |
70 |
≤200 |
no |
pass |
Results of the Dose Finding Assay
Sample |
Experiment 1 |
Experiment 2 |
|||
Concentration applied [µg/mL] |
Cell Viability [%] |
Concentration applied [µg/mL] |
Cell Viability [%] |
||
Medium Control |
-- |
-- |
97.40 |
-- |
95.50 |
Solvent Control |
DMSO |
-- |
97.60 |
-- |
95.50 |
Cyclic Glucamide C8-C10 |
C8 |
7.81 |
97.20 |
7.81 |
95.40 |
C7 |
15.63 |
97.30 |
15.63 |
95.30 |
|
C6 |
31.25 |
96.50 |
31.25 |
95.10 |
|
C5 |
62.50 |
97.20 |
62.50 |
95.30 |
|
C4 |
125.00 |
96.10 |
125.00 |
93.90 |
|
C3 |
250.00 |
94.20 |
250.00 |
87.70 |
|
C2 |
500.00 |
77.00 |
500.00 |
47.40 |
|
C1 |
1000.00 |
2.80 |
1000.00 |
7.70 |
|
Calculated CV75 [µg/mL] |
509.43 |
311.03 |
|||
Mean CV75 [µg/mL] |
410.23 |
||||
SD CV 75 [µg/mL] |
140.29 |
||||
CD54 and CD86 Expression Experiment 1
Sample |
Conc. |
Cell Viability [%] |
Mean Fluorescence Intensity |
corrected Mean Fluorescence Intensity |
Relative Fluorescence Intensity (RFI) |
Ratio Isotype IgG1 to [%] |
|||||||
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
CD86 |
CD54 |
CD86 |
CD54 |
||
Medium Control |
- |
96.3 |
96.9 |
96.9 |
1429 |
1058 |
559 |
870 |
499 |
83 |
102 |
256 |
189 |
Solvent Control |
0.20% |
96.8 |
96.6 |
96.8 |
1628 |
1072 |
585 |
1043 |
487 |
100 |
100 |
278 |
183 |
DNCB |
4.00 |
85.3 |
83.7 |
82.4 |
4362 |
2391 |
743 |
3619 |
1648 |
347 |
338 |
587 |
322 |
Cyclic Glucamide C8-C10 |
492.28 |
19.1 |
21.4 |
20.0 |
1730 |
1441 |
911 |
819 |
530 |
79 |
109 |
190 |
158 |
410.23 |
58.7 |
55.6 |
55.2 |
1752 |
1089 |
629 |
1123 |
460 |
108 |
94 |
279 |
173 |
|
341.86 |
78.2 |
76.3 |
75.8 |
1549 |
1127 |
602 |
947 |
525 |
91 |
108 |
257 |
187 |
|
284.88 |
83.0 |
82.4 |
81.9 |
1303 |
1186 |
680 |
623 |
506 |
60 |
104 |
192 |
174 |
|
237.40 |
86.5 |
86.6 |
84.5 |
1416 |
1110 |
560 |
856 |
550 |
82 |
113 |
253 |
198 |
|
197.84 |
89.7 |
89.2 |
88.8 |
1593 |
1034 |
577 |
1016 |
457 |
97 |
94 |
276 |
179 |
|
164.86 |
91.0 |
91.7 |
90.5 |
1443 |
1040 |
566 |
877 |
474 |
84 |
97 |
255 |
184 |
|
137.39 |
93.3 |
92.0 |
92.0 |
1560 |
1031 |
544 |
1016 |
487 |
97 |
100 |
287 |
190 |
|
CD54 and CD86 Expression Experiment 2
Sample |
Conc. |
Cell Viability [%] |
Mean Fluorescence Intensity |
corrected Mean Fluorescence Intensity |
Relative Fluorescence Intensity (RFI) |
Ratio Isotype IgG1 to [%] |
|||||||
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
Isotype IgG1 |
CD86 |
CD54 |
CD86 |
CD54 |
CD86 |
CD54 |
||
Medium Control |
- |
97.1 |
97.0 |
96.7 |
1275 |
870 |
539 |
736 |
331 |
100 |
68 |
237 |
161 |
Solvent Control |
0.20% |
97.3 |
96.8 |
96.8 |
1259 |
1011 |
523 |
736 |
488 |
100 |
100 |
241 |
193 |
DNCB |
4.0 |
82.6 |
81.2 |
79.6 |
2937 |
3013 |
687 |
2250 |
2326 |
306 |
477 |
428 |
439 |
Cyclic Glucamide C8-C10 |
492.28 |
27.7 |
26.1 |
25.9 |
1226 |
1165 |
695 |
531 |
470 |
72 |
96 |
176 |
168 |
410.23 |
56.7 |
56.7 |
54.7 |
1079 |
1239 |
632 |
447 |
607 |
61 |
124 |
171 |
196 |
|
341.86 |
67.5 |
67.5 |
67.7 |
1058 |
1241 |
619 |
439 |
622 |
60 |
127 |
171 |
200 |
|
284.88 |
79.8 |
77.9 |
77.5 |
1227 |
1243 |
557 |
670 |
686 |
91 |
141 |
220 |
223 |
|
237.40 |
84.4 |
84.6 |
84.4 |
1191 |
1144 |
562 |
629 |
582 |
85 |
119 |
212 |
204 |
|
197.84 |
88.5 |
88.2 |
87.3 |
1341 |
1096 |
543 |
798 |
553 |
108 |
113 |
247 |
202 |
|
164.86 |
91.5 |
90.8 |
90.8 |
1256 |
1011 |
516 |
740 |
495 |
101 |
101 |
243 |
196 |
|
137.39 |
93.0 |
92.7 |
93.1 |
1321 |
948 |
577 |
744 |
371 |
101 |
76 |
229 |
164 |
|
Acceptance Criteria
Acceptance Criterion |
Range |
Experiment 1 |
pass/fail |
Experiment 2 |
pass/fail |
||||
cell viability solvent controls [%] |
>90 |
96.3 |
- |
96.9 |
pass |
96.7 |
- |
97.3 |
pass |
number of test dosed with viability >50% CD86 |
≥4 |
7 |
pass |
7 |
pass |
||||
number of test dosed with viability >50% CD54 |
≥4 |
7 |
pass |
7 |
pass |
||||
number of test dosed with viability >50% IgG1 |
≥4 |
7 |
pass |
7 |
pass |
||||
RFI of positive control of CD86 |
≥150 |
347 |
pass |
306 |
pass |
||||
RFI of positive control of CD54 |
≥200 |
338 |
pass |
477 |
pass |
||||
RFI of solvent control of CD86 |
<150 |
120 |
pass |
100 |
pass |
||||
RFI of solvent control of CD54 |
<200 |
98 |
pass |
147 |
pass |
||||
MFI ratio CD86/IgG1 for medium control [%] |
>105 |
256 |
pass |
237 |
pass |
||||
MFI ratio CD86/IgG1 for DMSO control [%] |
>105 |
278 |
pass |
241 |
pass |
||||
MFI ratio CD54/IgG1for medium control [%] |
>105 |
189 |
pass |
161 |
pass |
||||
MFI ratio CD54/IgG1for DMSO control [%] |
>105 |
183 |
pass |
193 |
pass |
||||
Historical Data
Criterion |
mean |
SD |
N |
cell viability solvent controls [%] |
97.0 |
1.3 |
672 |
number of test doses with viability >50% |
- |
- |
1786 |
RFI of positive control of CD86 |
401.0 |
146.8 |
112 |
RFI of positive control of CD54 |
576.6 |
312.0 |
112 |
RFI of solvent control of CD86 |
115.0 |
15.1 |
112 |
RFI of solvent control of CD54 |
118.8 |
25.5 |
112 |
MFI ratio IgG1/CD86 for medium control [%] |
202.4 |
50.0 |
112 |
MFI ratio IgG1/CD86 for DMSO control [%] |
221.6 |
58.5 |
112 |
MFI ratio IgG1/CD54 for medium control [%] |
141.0 |
24.7 |
112 |
MFI ratio IgG1/CD54 for DMSO control [%] |
147.7 |
25.6 |
112 |
Results of the Cytotoxicity Measurement
|
Concentration [µM] |
Cell Viability [%] |
||||
Exp. 1 |
Exp. 2 |
Exp. 3 |
Mean |
SD |
||
Solvent Control |
- |
100.0 |
100.0 |
100.0 |
100.0 |
0.0 |
Positive Control |
4.00 |
107.0 |
100.4 |
99.0 |
102.1 |
4.3 |
8.00 |
104.0 |
105.8 |
110.2 |
106.7 |
3.2 |
|
16.00 |
116.8 |
111.0 |
111.0 |
113.0 |
3.3 |
|
32.00 |
107.4 |
116.5 |
111.9 |
112.0 |
4.5 |
|
64.00 |
104.4 |
118.9 |
108.3 |
110.5 |
7.5 |
|
Test Item |
0.98 |
111.5 |
105.6 |
82.0 |
99.7 |
15.6 |
1.95 |
87.4 |
98.7 |
90.4 |
92.2 |
5.8 |
|
3.91 |
95.3 |
99.7 |
86.8 |
93.9 |
6.6 |
|
7.81 |
98.7 |
96.7 |
87.3 |
94.2 |
6.1 |
|
15.63 |
101.8 |
99.0 |
90.1 |
96.9 |
6.1 |
|
31.25 |
93.2 |
89.2 |
86.8 |
89.8 |
3.2 |
|
62.50 |
123.0 |
97.0 |
84.9 |
101.6 |
19.5 |
|
125.00 |
93.5 |
89.7 |
84.4 |
89.2 |
4.6 |
|
250.00 |
87.7 |
83.2 |
69.5 |
80.1 |
9.5 |
|
500.00 |
70.7 |
74.5 |
58.9 |
68.0 |
8.1 |
|
1000.00 |
16.9 |
15.0 |
14.0 |
15.3 |
1.5 |
|
2000.00 |
0.6 |
0.4 |
0.5 |
0.5 |
0.1 |
|
Induction of Luciferase Activity Experiment 1
Experiment 1 |
Concentration [µM] |
Fold Induction |
Significance |
||||
Rep. 1 |
Rep. 2 |
Rep. 3 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.04 |
1.22 |
1.26 |
1.17 |
0.12 |
|
8.00 |
0.99 |
1.13 |
1.15 |
1.09 |
0.09 |
|
|
16.00 |
1.31 |
1.41 |
1.70 |
1.48 |
0.20 |
|
|
32.00 |
1.73 |
1.60 |
1.91 |
1.75 |
0.16 |
* |
|
64.00 |
3.89 |
2.91 |
3.34 |
3.38 |
0.49 |
* |
|
Test Item |
0.98 |
0.83 |
1.06 |
1.15 |
1.01 |
0.17 |
|
1.95 |
1.09 |
0.99 |
0.97 |
1.02 |
0.07 |
|
|
3.91 |
0.93 |
0.95 |
0.92 |
0.93 |
0.01 |
|
|
7.81 |
0.99 |
0.94 |
1.14 |
1.03 |
0.11 |
|
|
15.63 |
0.88 |
0.93 |
1.09 |
0.96 |
0.11 |
|
|
31.25 |
0.96 |
1.00 |
1.16 |
1.04 |
0.10 |
|
|
62.50 |
1.08 |
1.14 |
1.03 |
1.08 |
0.06 |
|
|
125.00 |
0.95 |
1.07 |
1.16 |
1.06 |
0.10 |
|
|
250.00 |
1.45 |
1.29 |
1.35 |
1.37 |
0.08 |
|
|
500.00 |
1.75 |
1.74 |
1.76 |
1.75 |
0.01 |
* |
|
1000.00 |
2.15 |
2.38 |
2.19 |
2.24 |
0.13 |
* |
|
2000.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
Induction of Luciferase Activity Experiment 2
Experiment 2 |
Concentration [µM] |
Fold Induction |
Significance |
||||
Rep. 1 |
Rep. 2 |
Rep. 3 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.03 |
0.99 |
0.99 |
1.00 |
0.02 |
|
8.00 |
0.96 |
1.08 |
0.99 |
1.01 |
0.06 |
|
|
16.00 |
1.23 |
1.29 |
1.28 |
1.27 |
0.03 |
|
|
32.00 |
1.46 |
1.64 |
1.48 |
1.53 |
0.10 |
* |
|
64.00 |
2.50 |
2.46 |
2.54 |
2.50 |
0.04 |
* |
|
Test Item |
0.98 |
0.85 |
0.98 |
1.00 |
0.94 |
0.08 |
|
1.95 |
0.90 |
0.86 |
0.87 |
0.87 |
0.02 |
|
|
3.91 |
0.94 |
1.02 |
0.91 |
0.96 |
0.05 |
|
|
7.81 |
0.89 |
0.90 |
0.84 |
0.88 |
0.03 |
|
|
15.63 |
0.85 |
0.94 |
1.18 |
0.99 |
0.17 |
|
|
31.25 |
0.88 |
0.95 |
0.83 |
0.88 |
0.06 |
|
|
62.50 |
1.30 |
0.99 |
0.90 |
1.07 |
0.21 |
|
|
125.00 |
1.02 |
1.03 |
0.87 |
0.97 |
0.09 |
|
|
250.00 |
1.26 |
1.16 |
1.03 |
1.15 |
0.12 |
|
|
500.00 |
1.44 |
1.50 |
1.37 |
1.43 |
0.07 |
|
|
1000.00 |
1.64 |
1.48 |
1.42 |
1.51 |
0.11 |
* |
|
2000.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
Induction of Luciferase Activity Experiment 3
Experiment 3 |
Concentration [µM] |
Fold Induction |
Significance |
||||
Rep. 1 |
Rep. 2 |
Rep. 3 |
Mean |
SD |
|||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.17 |
1.01 |
1.14 |
1.11 |
0.08 |
|
8.00 |
1.30 |
1.14 |
1.20 |
1.21 |
0.08 |
|
|
16.00 |
1.59 |
1.30 |
1.33 |
1.41 |
0.16 |
|
|
32.00 |
1.89 |
1.85 |
1.78 |
1.84 |
0.06 |
* |
|
64.00 |
3.14 |
3.68 |
3.16 |
3.32 |
0.30 |
* |
|
Test Item |
0.98 |
1.37 |
1.15 |
1.26 |
1.26 |
0.11 |
|
1.95 |
1.20 |
1.08 |
1.29 |
1.19 |
0.10 |
|
|
3.91 |
1.08 |
1.11 |
1.05 |
1.08 |
0.03 |
|
|
7.81 |
0.99 |
0.94 |
1.08 |
1.00 |
0.07 |
|
|
15.63 |
1.07 |
1.00 |
1.04 |
1.04 |
0.04 |
|
|
31.25 |
0.99 |
1.02 |
1.00 |
1.00 |
0.01 |
|
|
62.50 |
1.01 |
0.99 |
1.06 |
1.02 |
0.04 |
|
|
125.00 |
0.99 |
1.07 |
1.00 |
1.02 |
0.04 |
|
|
250.00 |
1.10 |
0.95 |
1.11 |
1.05 |
0.09 |
|
|
500.00 |
1.14 |
1.21 |
1.23 |
1.19 |
0.05 |
|
|
1000.00 |
0.94 |
0.73 |
0.66 |
0.78 |
0.14 |
|
|
2000.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
Induction of Luciferase Activity – Overall Induction
Overall Induction |
Conc. [µM] |
Fold Induction |
Significance |
||||
Exp. 1 |
Exp. 2 |
Exp. 3 |
Mean |
SD |
|
||
Solvent Control |
- |
1.00 |
1.00 |
1.00 |
1.00 |
0.00 |
|
Positive Control |
4.00 |
1.17 |
1.00 |
1.11 |
1.09 |
0.09 |
|
8.00 |
1.09 |
1.01 |
1.21 |
1.10 |
0.10 |
|
|
16.00 |
1.48 |
1.27 |
1.41 |
1.39 |
0.11 |
|
|
32.00 |
1.75 |
1.53 |
1.84 |
1.70 |
0.16 |
* |
|
64.00 |
3.38 |
2.50 |
3.32 |
3.07 |
0.50 |
* |
|
Test Item |
0.98 |
1.01 |
0.94 |
1.26 |
1.07 |
0.17 |
|
1.95 |
1.02 |
0.87 |
1.19 |
1.03 |
0.16 |
|
|
3.91 |
0.93 |
0.96 |
1.08 |
0.99 |
0.08 |
|
|
7.81 |
1.03 |
0.88 |
1.00 |
0.97 |
0.08 |
|
|
15.63 |
0.96 |
0.99 |
1.04 |
1.00 |
0.04 |
|
|
31.25 |
1.04 |
0.88 |
1.00 |
0.98 |
0.08 |
|
|
62.50 |
1.08 |
1.07 |
1.02 |
1.06 |
0.03 |
|
|
125.00 |
1.06 |
0.97 |
1.02 |
1.02 |
0.04 |
|
|
250.00 |
1.37 |
1.15 |
1.05 |
1.19 |
0.16 |
|
|
500.00 |
1.75 |
1.43 |
1.19 |
1.46 |
0.28 |
|
|
1000.00 |
2.24 |
1.51 |
0.78 |
1.51 |
0.73 |
|
|
2000.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
Additional Parameters
Parameter |
Exp. 1 |
Exp. 2 |
Exp. 3 |
Mean |
SD |
EC1.5[µM] |
337.79 |
921.83 |
n.a. |
629.81 |
292.02 |
Imax |
2.24 |
1.51 |
1.26 |
1.67 |
0.51 |
IC30[µM] |
506.15 |
537.84 |
245.63 |
429.87 |
160.34 |
IC50[µM] |
692.21 |
705.87 |
598.85 |
665.64 |
58.25 |
n.a. = not applicable
Acceptance Criteria
Criterion |
Range |
Exp. 1 |
pass/ |
Exp. 2 |
pass/ fail |
Exp. 3 |
pass/ |
CV Solvent Control |
< 20% |
11.6 |
pass |
8.3 |
pass |
7.2 |
pass |
No. of positive control concentration steps with significant luciferase activity induction >1.5 |
≥ 1 |
2.0 |
pass |
2.0 |
pass |
2.0 |
pass |
EC1.5 PC |
7 < x < 34 µM |
17.37 |
pass |
30.32 |
pass |
19.35 |
pass |
Induction PC at 64 µM |
2.00 < x |
3.38 |
pass |
2.50 |
pass |
3.32 |
pass |
Historical Data
Acceptance Criterion |
Range |
Mean |
SD |
N |
CV Solvent Control |
< 20% |
11.6 |
3.5 |
96 |
No. of positive control concentration steps with significant luciferase activity induction >1.5 |
≥ 1 |
2.4 |
0.6 |
96 |
EC1.5 PC |
7 < x < 34 µM |
18.5 |
6.0 |
96 |
Induction PC at 64 µM |
2.00 < x < 8.00 |
3.8 |
1.5 |
96 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
No skin sensitisation potential is observed in OECD 442C/D/E studies. Therefore, no classification is warrant for the substance according to CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
